Cargando…

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Despite the proven efficacy of combined immunochemotherapy (R-CHOP) in the majority of patients, ~40% of DLBCL patients do not respond or will relapse and consequently have a very poor prognosis. The development of targeted t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langendonk, Myra, de Jong, Mathilde R. W., Smit, Nienke, Seiler, Jonas, Reitsma, Bart, Ammatuna, Emanuele, Glaudemans, Andor W. J. M., van den Berg, Anke, Huls, Gerwin A., Visser, Lydia, van Meerten, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901714/ https://www.ncbi.nlm.nih.gov/pubmed/35256592 http://dx.doi.org/10.1038/s41408-022-00631-7

Ejemplares similares

WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma
por: de Jong, Mathilde R. W., et al.
Publicado: (2020)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
por: de Jong, Mathilde R. W., et al.
Publicado: (2018)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
por: He, Yuan, et al.
Publicado: (2019)

Tumour necrosis as assessed with (18)F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
por: Kahle, Xaver U., et al.
Publicado: (2019)

Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance
por: Choukrani, Ghizlane, et al.
Publicado: (2023)

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
por: van Bommel, Peter E., et al.
Publicado: (2017)

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties
por: Vlaming, Martijn, et al.
Publicado: (2021)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
por: Visser, Nienke, et al.
Publicado: (2021)

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
por: van Doesum, Jaap A., et al.
Publicado: (2021)

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity
por: Ustyanovska Avtenyuk, Natasha, et al.
Publicado: (2021)

Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands
por: van Doesum, Jaap, et al.
Publicado: (2020)

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas
por: Wu, Rui, et al.
Publicado: (2016)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
por: Zhang, Zhi, et al.
Publicado: (2021)

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
por: Bordeaux, Jennifer M., et al.
Publicado: (2012)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

FDG-PET/CT in infections: the imaging method of choice?
por: Glaudemans, Andor W. J. M., et al.
Publicado: (2010)

Expert opinions in nuclear medicine: Finding the “holy grail” in infection imaging
por: Glaudemans, Andor W. J. M., et al.
Publicado: (2023)

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
por: Houtsma, Roos, et al.
Publicado: (2022)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness
por: Singh, Bhupendra, et al.
Publicado: (2011)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

Estrogen Receptor Expression and Estrogen Receptor‐independent Cytotoxic Effects of Tamoxifen on Malignant Rhabdoid Tumor Cells in vitro
por: Koshida, Shigeki, et al.
Publicado: (2002)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer
por: Peng, Wan-Xin, et al.
Publicado: (2021)

Patient complaints in radiology: 9-year experience at a European tertiary care center
por: van den Berg, Pieter F., et al.
Publicado: (2019)

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield
por: Montes de Jesus, F. M., et al.
Publicado: (2019)

Analyzing the Estrogen Receptor Status of Liver Metastases with [(18)F]-FES-PET in Patients with Breast Cancer
por: Boers, Jorianne, et al.
Publicado: (2021)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Tamoxifen Regulates Cell Fate Through Mitochondrial Estrogen Receptor Beta in Breast Cancer
por: Razandi, Mahnaz, et al.
Publicado: (2012)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
por: CHEN, MING, et al.
Publicado: (2013)

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
por: Chang, Bo Yoon, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c67eldfvfv3sqjgj0a4cjqhepu